Schell Jonathan C, Koenig Steven B, Bastin Kenneth, Wirostko William J
The Eye Institute, Department of Ophthalmology, Medical College of Wisconsin;
Radiation Oncology Associates Ltd., St Luke's Medical Center, Milwaukee, Wisconsin, USA.
Clin Pract. 2011 May 30;1(2):e39. doi: 10.4081/cp.2011.e39. eCollection 2011 May 16.
Ocular iris metastasis from lung cancer is uncommon. We report a patient with metastatic non-small cell lung cancer who was found to have a metastatic lesion to the iris. Local therapy for pain control and vision loss was administered with intracameral bevacizumab. Complete resolution of pain, improvement in vision, and near complete resolution of iris tumor were seen within two months. No ocular toxicity to anterior segment structures was detectable on corneal pachymetry and corneal specular microscopy. This is the first case report demonstrating safety and efficacy of intracameral bevacizumab for iris metastasis from non-small cell lung cancer.
肺癌眼部虹膜转移并不常见。我们报告了一例转移性非小细胞肺癌患者，其虹膜发现有转移病灶。通过前房内注射贝伐单抗进行局部治疗以控制疼痛和视力丧失。两个月内疼痛完全缓解，视力改善，虹膜肿瘤几乎完全消退。角膜测厚仪和角膜内皮显微镜检查未发现对眼前节结构有眼部毒性。这是首例证明前房内注射贝伐单抗治疗非小细胞肺癌虹膜转移安全性和有效性的病例报告。
